This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: C11 / Special Copayment Reduction: V193 / 5% copayment (for 5 years from the cancer registration date) |
| B. Synonyms | Nasopharyngeal cancer, epipharyngeal cancer, cancer of the nasopharynx, Nasopharyngeal carcinoma (NPC), Nasopharyngeal cancer |
| C. Adult onset | Very high — appears mainly in men in their 40s–60s; can rarely occur in children and adolescents |
| 1. History | Discovery of the association between EBV and nasopharyngeal cancer (1966), studies of the high-incidence region of southern China, changes in the WHO histologic classification |
| 2. Causes | EBV infection (main), nitrosamine-containing foods, smoking, alcohol, genetic predisposition |
| 3. Genetics | EBV integration, LMP1/EBNA expression, HLA association, 9p21 deletion, somatic variants |
| 4. General epidemiology | About 600–700 cases per year in Korea; 25–50 per 100,000 in southern China; most common in men in their 40s–60s |
| 5. Pathophysiology | EBV latency program type II, NF-κB activation by LMP1, epithelial cell immortalization |
| 6. Symptoms | Cervical lymphadenopathy, nasal obstruction, epistaxis, ear fullness, conductive hearing loss, diplopia, headache |
| 7. Signs | Cervical lymphadenopathy (60–70%), signs of cranial nerve involvement, elevated blood EBV-DNA |
| 8. Screening | EBV serology (VCA-IgA, EA-IgA), plasma EBV-DNA, nasopharyngoscopy for high-risk groups |
| 9. Diagnosis | Nasopharyngoscopy + biopsy, MRI (essential), CT, PET-CT, AJCC 8th edition TNM staging |
| 10. Treatment | IMRT concurrent chemoradiotherapy (standard), induction chemotherapy (GP regimen), immunotherapy (Keytruda, Opdivo) |
| 11. Prognosis | 5-year survival: stage I 90%↑, stage II 85%, stage III 70–80%, stage IV 40–60% |
| 12. Prevention | Limiting salted and smoked foods, smoking cessation, moderation of alcohol intake, monitoring of high-risk groups by EBV serology |
| 13. References | Chan ATC et al. Lancet 2010 and 9 other papers |
The history of nasopharyngeal carcinoma (NPC) dates back to the late 19th century. In 1901, the German pathologists Regaud and Reverchon first described a distinctive carcinoma arising in the nasopharynx, using the name 'lymphoepithelioma' at the time. This histologic type corresponds to nonkeratinizing undifferentiated carcinoma in the current WHO classification. From the 1950s, it was systematically confirmed that nasopharyngeal cancer has a very high incidence in Guangdong Province, China, and Hong Kong, which sparked research on gene–environment interactions.
The decisive turning point came in 1966, when Old et al. reported that patients with nasopharyngeal cancer also showed high-titer antibodies to Epstein-Barr virus (EBV), which had been found in the serum of patients with Burkitt lymphoma. Subsequently, in the 1970s, Gertrude and Werner Henle established that IgA antibody to the EBV viral capsid antigen (VCA) is a serum marker of nasopharyngeal cancer, which became the basis for large-scale screening in China. In 1976, the WHO histologically classified nasopharyngeal cancer into type 1 (keratinizing squamous cell carcinoma), type 2 (nonkeratinizing carcinoma), and type 3 (undifferentiated carcinoma), and in 2005 revised this to keratinizing and nonkeratinizing (differentiated/undifferentiated) types.
In Korea, accumulation of domestic data on nasopharyngeal cancer began in the 1980s as specialized head and neck cancer care became systematized. Korea is an intermediate-risk region with lower incidence of nasopharyngeal cancer than southern China and Southeast Asia, but the distribution of EBV-related histologic types is similar, confirming that the same pathophysiologic mechanisms operate. With the introduction of intensity-modulated radiotherapy (IMRT) in the 2000s, tumor control rates and quality of life improved greatly. Recently, as quantification of plasma EBV-DNA has been used for staging, treatment response monitoring, and prediction of residual cancer, the management of nasopharyngeal cancer in the era of precision medicine is taking concrete shape.
The causes of nasopharyngeal cancer show a multifactorial structure centered on EBV infection. EBV (Epstein-Barr virus) is detected in nearly all cases of nonkeratinizing and undifferentiated nasopharyngeal cancer and exists in episomal form in the nuclei of cancer cells. EBV exists as a latent infection in more than about 90% of adults worldwide, yet nasopharyngeal cancer has high incidence only in specific regions and ethnic groups, suggesting that EBV alone cannot explain cancer development and that environmental and genetic factors act together.
Among dietary factors, salted and smoked foods containing nitrosamines are important. Epidemiologic studies have repeatedly confirmed that the culture in Guangdong Province, China, of eating salted fish (Cantonese salted fish) from early childhood is associated with the high incidence of nasopharyngeal cancer. Nitrosamines directly cause DNA damage, promoting the malignant transformation of EBV-infected epithelial cells. Occupational exposure to inhaled carcinogens such as charcoal and wood smoke and formaldehyde is also reported as a risk factor.
Smoking is more strongly associated with keratinizing nasopharyngeal cancer (WHO type 1), and alcohol also acts as an independent risk factor. When smoking and drinking are combined, the risk shows a more-than-additive amplifying effect. Regarding genetic predisposition, specific HLA alleles such as HLA-A2, HLA-B17, and HLA-Bw46 are known to be associated with increased susceptibility to nasopharyngeal cancer, and a family history raises the risk 4–10-fold. Chronic inflammation of the nasopharynx, poor ventilation, and hygiene conditions are also mentioned as indirect risk factors.
The genetic background of nasopharyngeal cancer consists of a complex interaction between EBV viral genes and the host cell genome. In EBV-infected nasopharyngeal epithelial cells, the latency II program is activated, and EBNA-1, LMP1, LMP2A/B, and several EBV miRNAs are expressed. LMP1 continuously activates the NF-κB, PI3K/AKT, and JAK/STAT pathways through TNFR superfamily-like signaling, promoting cell proliferation and inhibiting apoptosis. EBNA-1 is essential for replication and maintenance of the EBV genome and also functions to evade intracellular antigen presentation.
Among host genome changes, 9p21 (CDKN2A/p16 deletion) is one of the most commonly observed somatic alterations in nasopharyngeal cancer. Deletions of chromosomes 3p, 9p, 11q, 13q, and 14q are also reported, and TP53 variants are more frequent in the keratinizing type. Genome-wide association studies (GWAS) have identified susceptibility loci such as the HLA region (6p21), TNFRSF19 (13q12), and MECOM (3q26). EBV miRNAs (the miR-BART family) downregulate apoptosis genes of the host cell such as PUMA and BIM, prolonging cell survival.
In terms of immunogenicity, nasopharyngeal cancer is characterized by high PD-L1 expression, which provides the biological basis for immune checkpoint inhibitor therapy. HER2 overexpression and EGFR overexpression have also been reported in some cases, and the potential for targeted therapy is being explored. Pharmacogenomically, sensitivity to platinum agents is associated with ERCC1 polymorphisms and XRCC1 variants, and DPYD variants related to 5-FU metabolism are also used to predict toxicity.
The regional differences in nasopharyngeal cancer incidence are among the most extreme of all cancers. Southern China (Guangdong, Guangxi) and Hong Kong have the world's highest incidence, reaching 20–50 per 100,000 population, and neighboring Southeast Asia (Singapore, Malaysia, Indonesia) and North Africa (Tunisia, Libya) are intermediate-incidence regions. In contrast, it is very rare in Western Europe and North America, at about 0.5–1 per 100,000.
Korea, at about 1.3–1.8 per 100,000 population (about 600–750 cases per year), is a low-to-intermediate-risk region, and according to data from the Korea Central Cancer Registry of the National Cancer Center, it accounts for about 0.3% of all cancers. By sex distribution, it occurs 2.5–3 times more often in men than in women, and by age it peaks in the 40s–60s. Unusually, nasopharyngeal cancer shows a bimodal distribution with a second, smaller peak in children and adolescents (ages 15–25), in whom almost all cases are EBV-related undifferentiated carcinoma.
Incidence is gradually declining even in high-incidence regions including China, owing to improved living conditions and dietary changes. However, first-generation Chinese immigrants maintain the high risk of their region of origin, while incidence tends to fall in the second and third generations, supporting the importance of environmental and dietary factors. With improved treatment outcomes, mortality continues to decline.
The pathogenesis of nasopharyngeal cancer is understood as a multistep process centered on latent EBV infection. EBV invades nasopharyngeal epithelial cells and establishes the latency II program. In this process, the viral gene product LMP1 functions as a CD40-like receptor in the cell membrane and continuously activates the NF-κB, AP-1, and JAK/STAT signaling pathways via TRAF (TNF receptor-associated factor) adaptor proteins. As a result, antiapoptotic proteins such as BCL-2 and BCL-XL are overexpressed and cell survival is prolonged.
At the same time, environmental carcinogens (nitrosamines, etc.) damage tumor suppressor genes such as p16/CDKN2A, TP53, and RB1, and cell-cycle checkpoints break down. EBV-encoded miRNAs (the BART miRNA family) suppress host apoptosis effectors such as PUMA, BID, and CASP3 and promote epithelial-mesenchymal transition (EMT), increasing invasiveness. EBV also induces immune tolerance in the tumor microenvironment. LMP1 increases PD-L1 expression, suppressing the function of tumor-infiltrating T cells, and creates an immunosuppressive environment through IL-10 and TGF-β secretion.
Consequently, EBV-infected epithelial cells complete malignant transformation through the stages of enhanced proliferative signaling, inhibition of apoptosis, immune evasion, induction of angiogenesis, and acquisition of invasive and metastatic capacity. Early on, intraepithelial dysplasia is often not seen, making early detection difficult, and cervical lymph node metastasis is already present at diagnosis in as many as 60–70%.
The symptoms of nasopharyngeal cancer vary with site and degree of progression, and early symptoms are nonspecific, so diagnosis is often delayed. The most common early symptom is cervical lymphadenopathy; about 60–70% of patients present with a painless lump in the neck as the first symptom. This is because early metastasis occurs to lymph nodes around the nasopharynx and in the upper neck (level II, V).
Nasal symptoms include unilateral nasal obstruction, postnasal drip, and recurrent epistaxis (nosebleeds). Otologic symptoms characteristically include conductive hearing loss, ear fullness, and tinnitus due to otitis media with effusion that develops when the Eustachian tube opening (fossa of Rosenmüller) in the lateral wall of the nasopharynx is blocked by tumor. When such otologic symptoms occur unilaterally in an adult, nasopharyngeal cancer must be considered in the differential. Headache appears with skull base invasion, typically a persistent dull pain in the temporal or occipital region.
In advanced cases, symptoms of cranial nerve involvement appear. Diplopia (abducens and oculomotor nerve palsy), facial hypoesthesia (trigeminal nerve), dysphagia, hoarseness (vocal cord paralysis), and tongue deviation due to hypoglossal nerve palsy are observed. With distant metastasis, systemic symptoms such as bone pain (bone metastasis), cough and bloody sputum (lung metastasis), and hepatomegaly (liver metastasis) occur. General symptoms of cancer such as general weakness, loss of appetite, and weight loss may also accompany.
The most prominent sign on physical examination is cervical lymphadenopathy. Typically, the jugulodigastric node in the upper lateral neck and nodes in the posterior cervical triangle are palpated as firm and nontender. Bilateral neck masses are not uncommon in nasopharyngeal cancer (about 30%), which distinguishes it from other head and neck cancers. The primary tumor can be seen directly by laryngoscopy or flexible nasopharyngoscopy, with asymmetric mucosal bulging or ulcerative lesions observed in the fossa of Rosenmüller (pharyngeal recess).
Among signs of cranial nerve involvement, abducens nerve palsy (cranial nerve VI) is the most common, causing monocular or binocular diplopia. Involvement of the trigeminal nerve (cranial nerve V) may cause facial hypoesthesia, and involvement of the oculomotor nerve (cranial nerve III) ptosis and pupillary dilation. Soft palate paralysis, dysphagia, and hoarseness are also signs seen in advanced lesions. Proptosis suggests orbital invasion.
In blood tests, quantification of plasma EBV-DNA is used as the key tumor marker of nasopharyngeal cancer. Pretreatment EBV-DNA levels are proportional to tumor burden, and conversion to negative after treatment is a prognostic factor. Elevated titers of VCA-IgA and EA-IgA antibodies are also specific findings, but plasma EBV-DNA is now preferred. Persistent detection or re-elevation of EBV-DNA after treatment indicates recurrence. Complete blood count may show anemia, and abnormal liver function suggests liver metastasis.
Currently in Korea there is no separate national cancer screening program for nasopharyngeal cancer. However, it is performed selectively according to clinical need at medical institutions with high awareness of high-risk groups, especially EBV-related cancers. In Guangdong Province, China, and Hong Kong, large-scale population screening using serum EBV VCA-IgA antibody testing has been conducted since the 1970s, greatly increasing the early detection rate.
As a newer approach, quantitative PCR testing of plasma EBV-DNA is becoming established as the most sensitive and specific screening tool for nasopharyngeal cancer. A large randomized controlled study conducted in Hong Kong (Chan et al., NEJM 2021) reported that screening with plasma EBV-DNA significantly increased the detection rate of early nasopharyngeal cancer and reduced mortality. The test is noninvasive, requiring only a single blood draw, with a reported sensitivity of about 96% and specificity of about 98.6%.
In high-risk groups (positive family history, origin from southern China, history of EBV-related cancer), direct observation by flexible nasopharyngoscopy is recommended. In this case, enhanced endoscopic techniques such as narrow-band imaging (NBI) help detect subtle vascular abnormalities and early mucosal changes. In the general adult population, the nasopharynx should be evaluated when unilateral otitis media with effusion persists, or when there is a neck mass of unknown cause or recurrent epistaxis.
Nasopharyngeal cancer is confirmed by nasopharyngoscopic biopsy. After the primary lesion is seen directly with a flexible or rigid nasopharyngoscope, forceps biopsy is performed. When the lesion is submucosal, results may be negative and repeat biopsy may be needed. When only cervical lymph nodes are palpable and the primary site is unclear, fine-needle aspiration cytology (FNA) of the cervical lymph node is performed first, and if EBV-positive undifferentiated carcinoma is confirmed, the nasopharynx should be strongly suspected as the primary site.
Among imaging studies, MRI is the most important test for evaluating skull base invasion, cavernous sinus invasion, and submucosal spread. Nasopharyngeal tumors show high signal intensity on T2-weighted images, and contrast-enhanced T1 images accurately evaluate invasion of intracranial structures. CT is used complementarily to confirm skull base bone destruction and evaluate cervical lymph node size and distribution. PET-CT is used to evaluate distant metastasis (distant lymph nodes, lung, liver, bone) and assess treatment response.
AJCC 8th edition TNM staging: T1 is confined to the nasopharynx or extends to the oropharynx/nasal cavity; T2 involves the parapharyngeal space; T3 involves skull base bone, pterygoid plates, or paranasal sinuses; T4 involves intracranial extension, cranial nerves, hypopharynx, orbit, or parotid gland. N1 is defined as unilateral cervical lymph nodes (6 cm or less, above the supraclavicular fossa), N2 as bilateral cervical nodes (6 cm or less), and N3 as larger than 6 cm or located below the clavicle. Plasma EBV-DNA quantification is used as an adjunct to staging, for treatment response monitoring, and for predicting residual disease/recurrence.
The mainstay of first-line treatment for nasopharyngeal cancer is radiotherapy, and surgery plays a limited role, such as removal of residual cervical lymph nodes after radiotherapy. The current standard radiation technique is intensity-modulated radiotherapy (IMRT), with the simultaneous integrated boost (SIB) approach as standard, delivering 70Gy (2.12Gy/fraction) to the nasopharyngeal primary site, 59.4Gy to high-risk prophylactic sites, and 54Gy to low-risk prophylactic sites. IMRT minimizes radiation exposure to normal structures around the tumor (parotid glands, spinal cord, optic nerves), markedly reducing late toxicities such as xerostomia and nerve damage.
The standard treatment for locally advanced nasopharyngeal cancer (stage II–IVA) is cisplatin-based concurrent chemoradiotherapy (CCRT). Cisplatin 100mg/m² every 3 weeks or 40mg/m² once weekly is most commonly combined. In high-risk patients (high EBV-DNA, N2–N3, multiple lymph nodes), induction chemotherapy with the GP regimen (gemcitabine 1000mg/m² + cisplatin 80mg/m², every 3 weeks) followed by CCRT is increasingly used, based on studies showing a survival benefit (SUN1531, etc.). A randomized study has also reported that capecitabine maintenance after CCRT improved progression-free survival.
For first-line treatment of recurrent/metastatic nasopharyngeal cancer, the GP regimen (gemcitabine + cisplatin) is standard, and adding immune checkpoint inhibitors to it has recently been becoming the standard. Combinations of PD-1 inhibitors such as camrelizumab and toripalimab with GP have greatly improved progression-free survival in first-line metastatic treatment (CAPTAIN-1st, JUPITER-02, etc.). Pembrolizumab and nivolumab are also used as second-line treatment. Cetuximab, which targets EGFR, is also being studied in combination with radiotherapy.
The prognosis of nasopharyngeal cancer differs greatly by stage at diagnosis, EBV-DNA level, histologic type, and treatment method. By AJCC 8th edition, 5-year overall survival is reported as about 90% or higher for stage I, about 85% for stage II, about 70–80% for stage III, about 55–70% for stage IVA, and about 20–40% for stage IVB (distant metastasis). Since the introduction of IMRT, overall survival has improved significantly, especially local control.
Plasma EBV-DNA is a powerful prognostic factor. The higher the pretreatment EBV-DNA level, the poorer the prognosis, and if EBV-DNA becomes negative within 6–8 weeks after completion of treatment, the prognosis is good. Conversely, persistent detection of EBV-DNA after treatment or re-elevation during follow-up strongly suggests residual cancer or recurrence and requires further evaluation. Studies using this as a basis for EBV-DNA-guided treatment adjustment (adaptive therapy) are in progress.
Histologically, undifferentiated carcinoma (WHO types 2 and 3) is highly radiosensitive and actually has a better prognosis than the keratinizing type. As for recurrence patterns, distant metastasis is more common than local recurrence, most often to the skeleton, lung, and liver, in that order. For local recurrence, stereotactic radiotherapy (SBRT) or reirradiation is used, and for distant metastasis, chemoimmunotherapy. With the recent introduction of immune checkpoint inhibitors, the prognosis of recurrent/metastatic nasopharyngeal cancer is also improving. In long-term follow-up, late radiation toxicities (xerostomia, radiation encephalopathy, neck fibrosis) have an important effect on quality of life.
Prevention of nasopharyngeal cancer centers on managing the major risk factors of EBV exposure and environmental and dietary factors. On the dietary side, it is important to minimize intake of nitrosamine-containing foods (salted fish, smoked meat, pickled vegetables). In particular, because exposure to high-salt and smoked foods from early childhood is associated with cancer risk, dietary education for children and adolescents is meaningful for prevention. Increasing intake of fresh vegetables and fruits and switching from traditional salted foods to refrigerated preservation are recommended.
Smoking cessation and moderation of alcohol intake have a clear preventive effect in lowering the risk of keratinizing nasopharyngeal cancer. Stopping both smoking and drinking reduces the risk by more than an additive amount. For occupational exposure to formaldehyde, wood dust, machine oil, and the like, wearing appropriate respiratory protective equipment is recommended. When a family member has nasopharyngeal cancer, regular monitoring using plasma EBV-DNA or serum EBV antibody testing contributes to early detection in high-risk groups.
Currently, preventive vaccines against EBV are in clinical development; vaccine research using EBV envelope proteins such as gp350 as antigens is in progress but has not reached commercialization. In high-incidence regions (Guangdong, Hong Kong), population screening programs using plasma EBV-DNA are contributing to higher early detection rates and lower mortality, and in Korea as well, introduction of EBV-DNA-based screening for high-risk groups such as those with a family history is being discussed.